Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/69923
Title: Hypofractionation vs. conventional radiotherapy fractionation in the conservative treatment of T1 glottic cancer: a prospective cohort study
Authors: Salas-Salas, B. G.
Domínguez-Nuez, D. J.
Cabrera, R.
Ferrera-Alayón, L.
Lloret Sáez-Bravo, Marta 
Lara Jiménez, Pedro Carlos 
UNESCO Clasification: 320101 Oncología
320111 Radiología
Keywords: Conservative Treatment
Larynx Cancer
Local Control
Overall Survival
Radiotherapy Scheme, et al
Issue Date: 2019
Journal: Clinical and Translational Oncology 
Abstract: Background: Definitive radiotherapy is an effective single-modality in T1 glottic cancer. Hypofractionated schemes could offer excellent results in a shorter treatment period. We aimed to evaluate the clinical outcomes and toxicity comparing conventional vs. hypofractionated radiotherapy treatment in T1N0M0-glottic cancer. Patients and Methods: Between Jan-1st, 2005 and August-1st, 2017, in a prospective cohort study, with 10-year follow-up, 138 patients were treated with conventional schedule 2 Gy/day, total dose 70 Gy/7 weeks (N = 71) or hypofractionated schedule 2, 2–2, 25 Gy/day, total dose 63, 8–63 Gy/5, 5 weeks (N = 67). Endpoints were clinical-response rate, local relapse-free survival (LRFS), laryngectomy-free survival (LFS), toxicity rates, relapse-free survival (RFS), metastasis-free survival (MFS), second tumour-free survival (2TFS), and overall survival (OS). Results: All patients showed a complete clinical response. No differences were found for LRFS (p = 0.869), LFS (p = 0.975), RFS (p = 0.767), MFS (p = 0.601), 2TFS (p = 0.293), or OS (p = 0.685). Acute toxicity for skin and mucosae was similar (p = 0.550 and p = 0.698). Acute laryngeal toxicity was higher in the hypofractionation group (p = 0.004), due to an increase in slight moderate grade. No differences in late laryngeal edema were found (p = 0.989). Conclusion: Radiotherapy offers high rate survival, local control, and larynx preservation after 5–10-year follow-up. A hypofractionation could be preferable, since it offers the same results as conventional with fewer treatment sessions.
URI: http://hdl.handle.net/10553/69923
ISSN: 1699-048X
DOI: 10.1007/s12094-019-02118-7
Source: Clinical and Translational Oncology [ISSN 1699-048X], v. 22, p. 151–157
Appears in Collections:Artículos
Show full item record

SCOPUSTM   
Citations

5
checked on Dec 4, 2022

WEB OF SCIENCETM
Citations

4
checked on Oct 2, 2022

Page view(s)

60
checked on Jan 1, 2022

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.